MDT

98.84

+0.35%↑

144.96

-0.77%↓

VEEV

219.1

+0.44%↑

HQY

86.84

+1.35%↑

NEOG

9.45

+0.43%↑

MDT

98.84

+0.35%↑

144.96

-0.77%↓

VEEV

219.1

+0.44%↑

HQY

86.84

+1.35%↑

NEOG

9.45

+0.43%↑

MDT

98.84

+0.35%↑

144.96

-0.77%↓

VEEV

219.1

+0.44%↑

HQY

86.84

+1.35%↑

NEOG

9.45

+0.43%↑

MDT

98.84

+0.35%↑

144.96

-0.77%↓

VEEV

219.1

+0.44%↑

HQY

86.84

+1.35%↑

NEOG

9.45

+0.43%↑

MDT

98.84

+0.35%↑

144.96

-0.77%↓

VEEV

219.1

+0.44%↑

HQY

86.84

+1.35%↑

NEOG

9.45

+0.43%↑

Kodu・Aktsiate loetelu・Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Suletud

SektorTervishoid

1.28 3.23

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.23

Max

1.28

Põhinäitajad
By Trading Economics
Sissetulek	-16M -13M
Müük	-15M 14M
Kasumimarginaal	-90.037
Töötajad	103
EBITDA	-16M -10M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+225% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	5. märts 2026

Turustatistika
By TradingEconomics
Turukapital	-65M 429M
Eelmine avamishind	-1.95
Eelmine sulgemishind	1.28

Uudiste sentiment

By Acuity

74%

26%

336 / 361 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

0.6863 / 0.72 Toetus ja vastupanu

Lexicon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

15. jaan 2026, 18:44 UTC

Suurimad hinnamuutused turgudel

Agenus Falls After $141 Million Zydus Deal Closes

15. jaan 2026, 17:51 UTC

Suurimad hinnamuutused turgudel

Galaxy Digital Climbs on Texas Data-Center Expansion Approval, Tokenized CLO Issuance

15. jaan 2026, 17:25 UTC

Suurimad hinnamuutused turgudel

ASML Exceeds $500 Billion in Market Value on TSMC's Blockbuster Spending Plans -- Update

15. jaan 2026, 23:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15. jaan 2026, 23:48 UTC

Market Talk

Nikkei May Decline as Enthusiasm Over Election Eases -- Market Talk

15. jaan 2026, 23:40 UTC

Market Talk

Gold Edges Lower Amid Abating Geopolitical Risks -- Market Talk

15. jaan 2026, 23:11 UTC

Market Talk

Global Equities Roundup: Market Talk

15. jaan 2026, 23:11 UTC

Market Talk

Ryman Healthcare's Resales Remain Key Concern -- Market Talk

15. jaan 2026, 23:01 UTC

Market Talk

New Zealand's Economy Enters An Upswing -- Market Talk

15. jaan 2026, 22:56 UTC

Market Talk

Tulu

Catalyst Metals Delivers a Beat With Record Gold Output -- Market Talk

15. jaan 2026, 22:51 UTC

Market Talk

James Hardie's Plant Closures Could Boost Profit by 2%-3% -- Market Talk

15. jaan 2026, 22:19 UTC

Omandamised, ülevõtmised, äriostud

Verizon Gets Final California Approval to Secure $9.6 Billion Frontier Deal -- WSJ

15. jaan 2026, 21:50 UTC

Market Talk

Tulu

Financial Services Roundup: Market Talk

15. jaan 2026, 21:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Energy & Utilities Roundup: Market Talk

15. jaan 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

15. jaan 2026, 21:27 UTC

Tulu

BlackRock Caps 2025 With Record $14 Trillion in Assets -- 3rd Update

15. jaan 2026, 21:15 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Global Commodities Roundup: Market Talk

15. jaan 2026, 21:11 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Global Equities Roundup: Market Talk

15. jaan 2026, 21:11 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Canada Antitrust Watchdog Confirms Review of Canadian Energy Deal -- Market Talk

15. jaan 2026, 20:10 UTC

Market Talk

U.S. Natural Gas Futures Settle Mixed -- Market Talk

15. jaan 2026, 20:04 UTC

Tulu

These Stocks Are Today's Movers: TSMC, ASML, Goldman, Morgan Stanley, BlackRock, Coinbase, Sandisk, and More -- Barrons.com

15. jaan 2026, 20:03 UTC

Market Talk

Oil Futures Fall As Iran Risk Premium Fades -- Market Talk

15. jaan 2026, 19:26 UTC

Market Talk

Silver Closes at Fresh High -- Market Talk

15. jaan 2026, 18:29 UTC

Suurimad hinnamuutused turgudel

Agenus Falls After $141M Zydus Deal Closes

15. jaan 2026, 18:20 UTC

Tulu

Wall Street Powers Nation's Biggest Banks to Record Year -- WSJ

15. jaan 2026, 17:56 UTC

Market Talk

Tulu

U.S. Bank Results Look Encouraging for European Peers -- Market Talk

15. jaan 2026, 17:20 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Auto & Transport Roundup: Market Talk

15. jaan 2026, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

15. jaan 2026, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

15. jaan 2026, 17:02 UTC

Omandamised, ülevõtmised, äriostud

KBC Group Completes Acquisition of 98.45% Stake in 365.bank From J&T Finance Group

Võrdlus sarnastega

Hinnamuutus

Lexicon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

225% tõus

12 kuu keskmine prognoos

Keskmine 4.03 USD 225%

Kõrge 6 USD

Madal 2.1 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Lexicon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi Lexicon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.6863 / 0.72Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Sentiment

By Acuity

336 / 361 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.